Cargando…

Progress on elimination of lymphatic filariasis in Sierra Leone

BACKGROUND: A baseline survey in 2007–2008 found lymphatic filariasis (LF) to be endemic in Sierra Leone in all 14 districts and co-endemic with onchocerciasis in 12 districts. Mass drug administration (MDA) with ivermectin started in 2006 for onchocerciasis and was modified to add albendazole in 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Koroma, Joseph B., Sesay, Santigie, Conteh, Abdul, Paye, Jusufu, Bah, Mohamed, Sonnie, Mustapha, Hodges, Mary H., Zhang, Yaobi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987388/
https://www.ncbi.nlm.nih.gov/pubmed/29866207
http://dx.doi.org/10.1186/s13071-018-2915-4
_version_ 1783329103955361792
author Koroma, Joseph B.
Sesay, Santigie
Conteh, Abdul
Paye, Jusufu
Bah, Mohamed
Sonnie, Mustapha
Hodges, Mary H.
Zhang, Yaobi
author_facet Koroma, Joseph B.
Sesay, Santigie
Conteh, Abdul
Paye, Jusufu
Bah, Mohamed
Sonnie, Mustapha
Hodges, Mary H.
Zhang, Yaobi
author_sort Koroma, Joseph B.
collection PubMed
description BACKGROUND: A baseline survey in 2007–2008 found lymphatic filariasis (LF) to be endemic in Sierra Leone in all 14 districts and co-endemic with onchocerciasis in 12 districts. Mass drug administration (MDA) with ivermectin started in 2006 for onchocerciasis and was modified to add albendazole in 2008 to include LF treatment. In 2011, after three effective MDAs, a significant reduction in microfilaraemia (mf) prevalence and density was reported at the midterm assessment. After five MDAs, in 2013, mf prevalence and density were again measured as part of a pre-transmission assessment survey (pre-TAS) conducted per WHO guidelines. METHODS: For the pre-TAS survey, districts were paired to represent populations of one million for impact assessment. One sentinel site selected from baseline and one spot check site purposefully selected based upon local knowledge of patients with LF were surveyed per pair (two districts). At each site, 300 people over five years of age provided mid-night blood samples and mf prevalence and density were determined using thick blood film microscopy. Results are compared with baseline and midterm data. RESULTS: At pre-TAS the overall mf prevalence was 0.54% (95% CI: 0.36–0.81%), compared to 0.30% (95% CI: 0.19–0.47) at midterm and 2.6% (95% CI: 2.3–3.0%) at baseline. There was a higher, but non-significant, mf prevalence among males vs females. Eight districts (four pairs) had a prevalence of mf < 1% at all sites. Two pairs (four districts) had a prevalence of mf > 1% at one of the two sites: Koinadugu 0.98% (95% CI: 0.34–2.85%) and Bombali 2.67% (95% CI: 1.41–5.00%), and Kailahun 1.56% (95% CI: 0.72–3.36%) and Kenema 0% (95% CI: 0.00–1.21%). CONCLUSIONS: Compared to baseline, there was a significant reduction of LF mf prevalence and density in the 12 districts co-endemic for LF and onchocerciasis after five annual LF MDAs. No statistically significant difference was seen in either measure compared to midterm. Eight of the 12 districts qualified for TAS. The other four districts that failed to qualify for TAS had historically high LF baseline prevalence and density and had regular cross-border movement of populations. These four districts needed to conduct two additional rounds of LF MDA before repeating the pre-TAS. The results showed that Sierra Leone continued to make progress towards the elimination of LF as a public health problem.
format Online
Article
Text
id pubmed-5987388
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-59873882018-07-10 Progress on elimination of lymphatic filariasis in Sierra Leone Koroma, Joseph B. Sesay, Santigie Conteh, Abdul Paye, Jusufu Bah, Mohamed Sonnie, Mustapha Hodges, Mary H. Zhang, Yaobi Parasit Vectors Research BACKGROUND: A baseline survey in 2007–2008 found lymphatic filariasis (LF) to be endemic in Sierra Leone in all 14 districts and co-endemic with onchocerciasis in 12 districts. Mass drug administration (MDA) with ivermectin started in 2006 for onchocerciasis and was modified to add albendazole in 2008 to include LF treatment. In 2011, after three effective MDAs, a significant reduction in microfilaraemia (mf) prevalence and density was reported at the midterm assessment. After five MDAs, in 2013, mf prevalence and density were again measured as part of a pre-transmission assessment survey (pre-TAS) conducted per WHO guidelines. METHODS: For the pre-TAS survey, districts were paired to represent populations of one million for impact assessment. One sentinel site selected from baseline and one spot check site purposefully selected based upon local knowledge of patients with LF were surveyed per pair (two districts). At each site, 300 people over five years of age provided mid-night blood samples and mf prevalence and density were determined using thick blood film microscopy. Results are compared with baseline and midterm data. RESULTS: At pre-TAS the overall mf prevalence was 0.54% (95% CI: 0.36–0.81%), compared to 0.30% (95% CI: 0.19–0.47) at midterm and 2.6% (95% CI: 2.3–3.0%) at baseline. There was a higher, but non-significant, mf prevalence among males vs females. Eight districts (four pairs) had a prevalence of mf < 1% at all sites. Two pairs (four districts) had a prevalence of mf > 1% at one of the two sites: Koinadugu 0.98% (95% CI: 0.34–2.85%) and Bombali 2.67% (95% CI: 1.41–5.00%), and Kailahun 1.56% (95% CI: 0.72–3.36%) and Kenema 0% (95% CI: 0.00–1.21%). CONCLUSIONS: Compared to baseline, there was a significant reduction of LF mf prevalence and density in the 12 districts co-endemic for LF and onchocerciasis after five annual LF MDAs. No statistically significant difference was seen in either measure compared to midterm. Eight of the 12 districts qualified for TAS. The other four districts that failed to qualify for TAS had historically high LF baseline prevalence and density and had regular cross-border movement of populations. These four districts needed to conduct two additional rounds of LF MDA before repeating the pre-TAS. The results showed that Sierra Leone continued to make progress towards the elimination of LF as a public health problem. BioMed Central 2018-06-04 /pmc/articles/PMC5987388/ /pubmed/29866207 http://dx.doi.org/10.1186/s13071-018-2915-4 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Koroma, Joseph B.
Sesay, Santigie
Conteh, Abdul
Paye, Jusufu
Bah, Mohamed
Sonnie, Mustapha
Hodges, Mary H.
Zhang, Yaobi
Progress on elimination of lymphatic filariasis in Sierra Leone
title Progress on elimination of lymphatic filariasis in Sierra Leone
title_full Progress on elimination of lymphatic filariasis in Sierra Leone
title_fullStr Progress on elimination of lymphatic filariasis in Sierra Leone
title_full_unstemmed Progress on elimination of lymphatic filariasis in Sierra Leone
title_short Progress on elimination of lymphatic filariasis in Sierra Leone
title_sort progress on elimination of lymphatic filariasis in sierra leone
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987388/
https://www.ncbi.nlm.nih.gov/pubmed/29866207
http://dx.doi.org/10.1186/s13071-018-2915-4
work_keys_str_mv AT koromajosephb progressoneliminationoflymphaticfilariasisinsierraleone
AT sesaysantigie progressoneliminationoflymphaticfilariasisinsierraleone
AT contehabdul progressoneliminationoflymphaticfilariasisinsierraleone
AT payejusufu progressoneliminationoflymphaticfilariasisinsierraleone
AT bahmohamed progressoneliminationoflymphaticfilariasisinsierraleone
AT sonniemustapha progressoneliminationoflymphaticfilariasisinsierraleone
AT hodgesmaryh progressoneliminationoflymphaticfilariasisinsierraleone
AT zhangyaobi progressoneliminationoflymphaticfilariasisinsierraleone